Home › Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Jan 03, 2018

NEW YORK (360Dx) – Cancer detection firm Oncimmune announced on Tuesday that it has signed a licensing agreement for its EarlyCDT autoantibody-based diagnostics platform in China.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Cancer

  1. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  2. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  3. Synlab Pharma, Biotype Collaborate on Gastrointestinal, Endometrial Cancers

  4. Guardant Health to Launch Cell-Free DNA Assay for Cancer Recurrence Monitoring in 2019

    Premium

  5. MIT Spinout Glympse Bio Developing Dx Platform That Measures Disease State Inside, Outside of Body

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.